Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Mariana Reza"'
Publikováno v:
BMC Medical Imaging, Vol 18, Iss 1, Pp 1-8 (2018)
Abstract Background The Bone Scan Index (BSI) is used to quantitatively assess the total tumour burden in bone scans of patients with metastatic prostate cancer. The clinical utility of BSI has recently been validated as a prognostic imaging biomarke
Externí odkaz:
https://doaj.org/article/1f7efd5739844cb78e7eb0c32526b437
Autor:
Kurt Miller, Anup Patel, Lars Edenbrandt, Andrea Tubaro, Anders Bjartell, Teuvo L.J. Tammela, Per Wollmer, Wim P.J. Witjes, Manfred P. Wirth, Peter F.A. Mulders, Ola Thorsson, Mattias Ohlsson, Christien Caris, Frans M.J. Debruyne, Francisco Gómez Veiga, Mariana Reza, Elin Trägårdh, Virgilio Cicalese
Publikováno v:
European Urology Oncology, 4, 49-55
European Urology Oncology, 4, 1, pp. 49-55
European Urology Oncology, 4, 1, pp. 49-55
Contains fulltext : 233937.pdf (Publisher’s version ) (Closed access) BACKGROUND: Owing to the large variation in treatment response among patients with high-risk prostate cancer, it would be of value to use objective tools to monitor the status of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::82f534f505407e2dbc8d6597545f711f
https://doi.org/10.1016/j.euo.2019.05.002
https://doi.org/10.1016/j.euo.2019.05.002
Autor:
Lars Edenbrandt, R. Jones, Karim Fizazi, Mika Mustonen, Christophe Massard, Elin Trägårdh, Leena Mattila, Per Wollmer, Eva Bondesson, Mariana Reza, Anders Bjartell, John Aspegren
Publikováno v:
European Urology Focus. 2:547-552
Background\ud \ud ODM-201, a new-generation androgen receptor inhibitor, has shown clinical efficacy in prostate cancer (PCa). Quantitative methods are needed to accurately assess changes in bone as a measurement of treatment response. The Bone Scan
Publikováno v:
Clinical physiology and functional imaging.
Bone Scan Index (BSI) is a validated imaging biomarker to objectively assess tumour burden in bone in patients with prostate cancer, and can be used to monitor treatment response. It is not known if BSI is significantly altered when images are acquir
Publikováno v:
BMC Medical Imaging
BMC Medical Imaging, Vol 18, Iss 1, Pp 1-8 (2018)
BMC Medical Imaging, Vol 18, Iss 1, Pp 1-8 (2018)
Background The Bone Scan Index (BSI) is used to quantitatively assess the total tumour burden in bone scans of patients with metastatic prostate cancer. The clinical utility of BSI has recently been validated as a prognostic imaging biomarker. Howeve
Autor:
Anders Bjartell, David Minarik, Elin Trägårdh, Aseem Anand, Reza Kaboteh, Lars Edenbrandt, Mariana Reza, Steven M. Larson, Naofumi Matsunaga, Michael J. Morris
The effect of the procedural variability in image acquisition on the quantitative assessment of bone scan is unknown. Here, we have developed and performed preanalytical studies to assess the impact of the variability in scanning speed and in vendor-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::faef6dde403dfb0a104a431ab9e2c164
https://europepmc.org/articles/PMC6952052/
https://europepmc.org/articles/PMC6952052/
Autor:
Ola Thorsson, Lars Edenbrandt, Kurt Miller, Anup Patel, Andrea Tubaro, Mariana Reza, Anders Bjartell, Elin Trägårdh, Teuvo L.J. Tammela, Per Wollmer, Mattias Ohlsson, Francisco Gómez Veiga, Christien Caris, Wim P.J. Witjes, Frans M.J. Debruyne, Manfred P. Wirth, Virgilio Cicalese
Publikováno v:
Journal of Clinical Oncology. 34:e16599-e16599
e16599Background: The Zeus/SPCG11 study is a randomized controlled clinical trial with the aim to assess the efficacy of zoledronic acid (ZA) in preventing bone metastases in high-risk prostate cancer (PCa) patients. Bone Scan Index (BSI) reflects th
Autor:
Mariana Reza, Reza Kaboteh, Lars Edenbrandt, Sarah Lindgren Belal, Anders Bjartell, David Minarik, Aseem Anand, Andreas Joseffson
Publikováno v:
Journal of Clinical Oncology. 33:5044-5044
5044 Background: A consistent imaging biomarker to standardize the evaluation of change in bone scan is an unmet need for patients (pts) with bone metastasis. BSI is quantitative interpretation of ...
Autor:
Elin Trägårdh, Lars Edenbrandt, Reza Kaboteh, Mattias Ohlsson, Aseem Anand, Ingela Franck Lissbrant, Mariana Reza, Anders Bjartell, Per Wollmer, Till Eichenauer, Jan-Erik Damber, Lars Budäus
Publikováno v:
Journal of Clinical Oncology. 33:217-217
217 Background: Bone Scan Index (BSI) is a quantitative measurement that reflects the tumor burden in bone calculated from bone scintigraphy. It also represents a prognostic marker in patients (pts) with metastatic castration resistant prostate cance
Publikováno v:
Journal of Clinical Oncology. 33:288-288
288 Background: Enzalutamide (ENZ), an androgen receptor antagonist therapy, was approved for patients (pts) with mCRPC. However, in standard of care for mCRPC pts, change in prostate specific antigen (PSA) is not accepted as an efficacy response mea